Neurocare Plus Competitors

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

Lumosity is a leading brain training program, brought to you by Lumos Labs, Inc. Lumosity’s web and mobile games are designed by scientists to challenge core cognitive abilities. Lumosity’s scientists take neuropsychological and cognitive research tasks, or design new ones, and work with game designers to transform them into 50+ cognitive games. Designed to be both fun and adaptively challenging, Lumosity’s training program is accessible to people of all ages — helping them stay challenged to the full extent of their abilities. Lumos Labs also has a collaborative research initiative, the Human Cognition Project, which currently partners with over 90 university collaborators. Through the HCP, we grant qualified researchers free access to Lumosity’s cognitive training tasks, assessments, research tools, and, in some cases, limited access to data on cognitive task performance — helping them conduct larger, faster, and more efficient studies. For more information, please visit http://www.lumosity.com/hcp

Welcome to Akili! At Akili, we believe there is potential for medicine to be developed, delivered and experienced in a completely different way. We’re bringing together world-class neuroscience with exceptional creativity and video game development to challenge the status quo of medicine. Our digital medicine is not delivered through a pill, but rather through a patented and captivating video game experience. Effective medicine that’s captivating and enjoyable to use – now that’s refreshing! We're continuously evaluating new technologies and are advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity/ disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases. And we're always looking for game-changers to join our team – to help us change the status quo of medicine and ignite new hope for those living with cognitive deficits. Imagine what medicine can be®